Table of Contents
Introduction
GLP-1 receptor agonists are a group of medicines used to treat type 2 diabetes and obesity. These drugs work by copying the action of a natural hormone in the body called glucagon-like peptide-1, or GLP-1. This hormone helps lower blood sugar by increasing the release of insulin, slowing down digestion, and reducing appetite. Because of these effects, GLP-1 receptor agonists are useful for both managing blood sugar and helping with weight loss.
Over the last few years, these medicines have become more popular. Some of the most common GLP-1 receptor agonists include liraglutide (Victoza and Saxenda), dulaglutide (Trulicity), exenatide (Byetta and Bydureon), and semaglutide (Ozempic, Wegovy, and Rybelsus). They are used by people with type 2 diabetes to improve blood sugar control and by people without diabetes to help with weight loss, especially in cases of obesity. Wegovy, which contains semaglutide, is approved by the U.S. Food and Drug Administration (FDA) for weight loss. Ozempic, also semaglutide, is approved for diabetes but is sometimes used off-label for weight loss.
Because of this growing interest, especially in weight loss, more people are starting these drugs. However, not everyone can take GLP-1 receptor agonists safely. These medications can cause side effects and may be harmful for certain groups of people. It is important to know who should not take these drugs and what side effects to look out for. Understanding these risks can help prevent serious health problems.
Some people have medical conditions that make taking GLP-1 receptor agonists unsafe. For example, these drugs should not be used by people who have a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma. They are also not safe for people who have a rare condition called multiple endocrine neoplasia syndrome type 2. People with severe digestive problems or a history of pancreatitis should also be cautious. These are called contraindications—medical reasons why a drug should not be used.
Besides contraindications, there are other safety concerns. Even for people who are allowed to use GLP-1 receptor agonists, the drugs can still cause side effects. These side effects are usually not dangerous, but they can still make treatment hard to manage. The most common ones include nausea, vomiting, and diarrhea. These symptoms often happen when starting the medicine or increasing the dose, but they usually get better over time. In some cases, the side effects can be more serious. There have been reports of inflammation of the pancreas, changes in kidney function, and gallbladder problems.
Another safety concern is how GLP-1 receptor agonists interact with other medicines. Because they slow down how fast food moves through the stomach, they can also slow down the absorption of other drugs taken by mouth. This can affect how well those other medicines work. It is also important to watch out for low blood sugar, especially if a GLP-1 agonist is used together with insulin or other diabetes medications like sulfonylureas.
Women who are pregnant or breastfeeding also need to be careful. These drugs are not recommended during pregnancy because they may harm the baby. There is not enough research to know if they are safe while breastfeeding, so doctors often advise stopping the medicine if a woman is planning to get pregnant or is already pregnant.
As more people hear about GLP-1 receptor agonists through ads, social media, and word of mouth, it becomes more important to share clear and accurate information. These medicines can be very helpful, but they must be used with care. Understanding when they are safe and when they are not is key to avoiding harm. Anyone considering these medications needs to understand the full picture—the benefits, the risks, and the medical conditions that could make them unsafe.
What Are GLP-1 Receptor Agonists and How Do They Work?
GLP-1 receptor agonists are a group of medicines used to treat type 2 diabetes and, more recently, obesity. They help lower blood sugar levels and support weight loss. These drugs work by copying the actions of a natural hormone in the body called GLP-1, which stands for glucagon-like peptide-1.
GLP-1 is a hormone made in the gut after eating. It tells the body to release insulin, which lowers blood sugar. It also slows down how quickly the stomach empties and helps people feel full longer. This helps control blood sugar and reduce hunger, which may lead to weight loss.
How GLP-1 Agonists Help Lower Blood Sugar
The pancreas makes insulin, a hormone that allows sugar from food to enter cells and be used for energy. In people with type 2 diabetes, the body does not use insulin well, and the pancreas may not make enough of it. As a result, blood sugar levels stay high.
GLP-1 receptor agonists work by:
- Increasing insulin when blood sugar is high.
- Stopping the release of glucagon, a hormone that raises blood sugar.
- Slowing stomach emptying, which helps control how fast sugar enters the blood.
- Reducing appetite, which can lead to eating less and losing weight.
These actions make GLP-1 receptor agonists effective for people with type 2 diabetes, especially those who struggle with high blood sugar after meals.
How GLP-1 Agonists Help With Weight Loss
Some GLP-1 agonists are also approved to treat obesity, even in people without diabetes. The main reason is that these drugs make people feel full sooner and for longer. When the stomach empties more slowly, it sends signals to the brain that reduce hunger. People eat smaller meals and fewer snacks, which helps with weight loss over time.
Weight loss from GLP-1 agonists may also improve blood pressure, cholesterol, and other health risks related to obesity.
Common GLP-1 Agonist Medications
There are several GLP-1 receptor agonists available. Some are used once a day, while others are given once a week. All are taken as injections, though some pills are also available.
Here are some of the most common GLP-1 medications:
- Exenatide (Byetta, Bydureon): One of the first drugs in this class. It is given by injection either twice a day (Byetta) or once a week (Bydureon).
- Liraglutide (Victoza, Saxenda): Taken once daily. Victoza is used for type 2 diabetes, while Saxenda is approved for weight loss.
- Dulaglutide (Trulicity): A once-weekly injection for type 2 diabetes.
- Semaglutide (Ozempic, Wegovy, Rybelsus): Ozempic is for type 2 diabetes, Wegovy for weight loss, and Rybelsus is the pill form of semaglutide.
These medications have different doses and forms, but they all work in a similar way—by activating GLP-1 receptors in the body.
How the Drugs Are Taken
Most GLP-1 agonists are injected under the skin. Depending on the drug, injections may be needed daily or weekly. Some versions, like Rybelsus (semaglutide), come in pill form and are taken by mouth once a day.
When starting these medications, doctors usually begin with a low dose. This helps the body adjust and lowers the chance of side effects. Over time, the dose may be slowly increased to reach the full effect.
Safety and Monitoring
GLP-1 receptor agonists are not insulin. They are often used with other diabetes medicines, but they can also be used alone. People taking these drugs need regular checkups to monitor blood sugar, weight, and possible side effects. While they are effective, they are not right for everyone. Knowing who can and cannot take them is important for safe use.
GLP-1 receptor agonists are helpful tools in managing type 2 diabetes and obesity. They work by copying a hormone that improves insulin release, reduces hunger, and slows digestion. Several types are available, each with different dosing schedules, but they all aim to improve blood sugar and support weight loss.
What Are the Most Common Side Effects of GLP-1 Agonists?
GLP-1 receptor agonists are a group of medicines used to help manage blood sugar in people with type 2 diabetes. They are also approved for weight loss in some cases. While these medicines can be helpful, they can also cause side effects. Some side effects are mild and temporary. Others can be more serious and may need medical attention. Understanding the most common side effects helps patients and healthcare providers work together to manage them safely.
Gastrointestinal Side Effects
The most common side effects of GLP-1 agonists are related to the stomach and intestines. These are known as gastrointestinal (GI) side effects. They include:
- Nausea
Nausea is the most frequently reported side effect. It often starts when the medicine is first given or when the dose is increased. Most people feel better after a few days or weeks as the body gets used to the drug. Eating smaller meals, avoiding greasy foods, and not lying down right after eating can help reduce nausea. - Vomiting
Some people may vomit, especially if the nausea is strong. Vomiting can also occur after eating large meals or foods that upset the stomach. In most cases, vomiting lessens with time. Drinking fluids and staying hydrated is important. - Diarrhea
Loose stools or diarrhea may happen during treatment. It can be mild or bothersome. Like other GI symptoms, diarrhea often improves over time. If it becomes severe or leads to dehydration, a healthcare provider should be contacted. - Constipation
Some patients experience constipation instead of diarrhea. This may be due to slower movement of food through the stomach and intestines. Drinking more water, eating fiber-rich foods, and staying active can help.
These side effects are linked to how GLP-1 agonists work. They slow down how fast food leaves the stomach, which helps control appetite and blood sugar. But this slower digestion can also cause stomach problems. These effects are most common when starting treatment and usually get better with time.
Headache
Headaches are another side effect reported by people taking GLP-1 drugs. The cause is not always clear. It may be due to dehydration, changes in blood sugar, or the body adjusting to the new medicine. Headaches are usually mild. Drinking enough water and checking blood sugar levels regularly can help manage this symptom.
Fatigue
Feeling tired or low on energy is a side effect that some patients notice. This may be from reduced food intake, changes in blood sugar, or the body working harder to adjust to the medicine. If fatigue continues or worsens, it may be a sign of another problem, such as low blood sugar or thyroid changes, and should be checked by a provider.
Injection Site Reactions
GLP-1 agonists are usually given as injections under the skin, often once a week or daily. Some people may notice redness, itching, swelling, or discomfort at the injection site. These reactions are often mild and go away within a few hours or days. Changing the spot where the injection is given each time can help reduce irritation.
Dose-Dependent and Timing Effects
Side effects often depend on the dose. They are more likely or stronger when the dose is increased. That’s why most treatment plans start with a low dose and slowly raise it. This helps the body adjust and reduces the chances of side effects. Most symptoms happen early in treatment, especially during the first few weeks.
Frequency in Clinical Trials and Real-Life Use
In clinical studies, many people reported mild to moderate side effects. Nausea was the most common, affecting about 20% to 40% of users, depending on the drug and dose. Vomiting and diarrhea happened in about 5% to 15% of users. Headaches and fatigue were less common. Most people were able to continue using the medicine as side effects usually got better over time.
In real-life use, the numbers may vary slightly. Some people may stop taking the drug because of how it makes them feel. For others, these effects are manageable with small changes in diet, hydration, and how the medicine is taken.
Most of the side effects linked to GLP-1 receptor agonists are related to the stomach and digestion. These effects are usually not dangerous and often go away on their own. Starting with a low dose and following medical advice can help reduce these problems. Still, some people may need to stop the medicine if the side effects are too strong or do not improve. Recognizing and managing these common issues is an important part of using GLP-1 drugs safely.
Who Should Not Take GLP-1 Receptor Agonists? (Absolute Contraindications)
GLP-1 receptor agonists are powerful medications used to treat type 2 diabetes and obesity. They help lower blood sugar, support weight loss, and may reduce the risk of heart disease in some people. However, there are certain situations where these medications should not be used at all. These are called absolute contraindications—conditions or factors that make the use of a drug dangerous and possibly life-threatening. In these cases, using a GLP-1 receptor agonist could cause serious harm.
Personal or Family History of Medullary Thyroid Carcinoma (MTC)
People who have a personal history of medullary thyroid carcinoma (MTC) should never take GLP-1 receptor agonists. MTC is a rare but aggressive type of thyroid cancer that starts in the parafollicular C-cells of the thyroid gland. These cells produce a hormone called calcitonin. Some GLP-1 medications have been shown in animal studies to cause tumors in these cells.
Even though this cancer risk has not been clearly proven in humans, the U.S. Food and Drug Administration (FDA) requires a black box warning on these medications. This is the strongest type of warning given for prescription drugs. Because of this risk, anyone with a personal or family history of MTC should avoid GLP-1 receptor agonists.
Before prescribing these medications, doctors often ask about family members who have had thyroid cancer. If a parent, sibling, or child has had MTC, the risk is considered too high, and a different type of medicine should be chosen.
Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)
People with Multiple Endocrine Neoplasia Syndrome type 2 (MEN 2) should also avoid GLP-1 receptor agonists. MEN 2 is a rare inherited disorder that causes tumors in hormone-producing glands, especially the thyroid and adrenal glands. One of the most common tumors seen in MEN 2 is medullary thyroid carcinoma, the same type of cancer discussed above.
Because people with MEN 2 have a high chance of developing MTC, using GLP-1 receptor agonists could increase their cancer risk even more. This condition is usually diagnosed with genetic testing, and family history plays a big role in identifying who might be at risk. People who know they carry a gene mutation linked to MEN 2 should not take these drugs.
Hypersensitivity to Drug Components
A person who has a severe allergic reaction (hypersensitivity) to any ingredient in a GLP-1 receptor agonist should never use that medication again. Symptoms of a serious allergic reaction can include rash, itching, swelling of the face or throat, severe dizziness, or trouble breathing. These symptoms may happen after the first dose or after repeated use.
If someone has experienced these symptoms in the past after taking a GLP-1 drug, the medication should be stopped right away. It is unsafe to continue or try a different GLP-1 drug without expert medical guidance. Some people may react to the drug itself, while others may be allergic to one of the inactive ingredients in the injection solution.
Doctors may refer patients to an allergist if there is any question about drug safety due to past allergic reactions.
Severe Gastrointestinal Disease (Especially Gastroparesis)
People with severe gastrointestinal (GI) problems, especially gastroparesis, should not take GLP-1 receptor agonists. Gastroparesis is a condition where the stomach muscles do not work properly, causing delayed emptying of food into the intestines. This can lead to symptoms like nausea, vomiting, bloating, and early fullness after eating.
GLP-1 receptor agonists work by slowing stomach emptying, which helps with blood sugar control and weight loss. However, in people who already have gastroparesis or other serious GI issues, this effect can make their condition worse. It can lead to more severe nausea, vomiting, and even dehydration.
Doctors may perform special tests to check for gastroparesis before starting GLP-1 medications, especially in people who already have stomach-related symptoms or a long history of diabetes.
GLP-1 receptor agonists can offer many health benefits, but they are not right for everyone. Some health conditions make the use of these drugs too risky. People with a history of MTC, those who have MEN 2, anyone who has had a serious allergic reaction to the drug, or those with severe stomach problems should avoid GLP-1 agonists completely. Before starting any new treatment, doctors carefully review medical history to make sure the medication is safe to use.
Medical Conditions That Require Caution With GLP-1 Receptor Agonists
GLP-1 receptor agonists are generally well tolerated, but people with certain health conditions may face higher risks when using them. These drugs affect several body systems, including the digestive tract, pancreas, and kidneys. For this reason, careful review of a person’s full medical history is important before starting treatment. The following conditions may require extra caution or monitoring.
History of Pancreatitis
Pancreatitis means inflammation of the pancreas. This organ plays a key role in digestion and blood sugar control. People who have had pancreatitis before may be at higher risk of having it again, especially when taking medications that affect the pancreas.
GLP-1 receptor agonists have been linked to rare cases of pancreatitis. While research does not clearly show that these drugs directly cause pancreatitis, some studies have raised concerns. Because of this, people with a history of pancreatitis are often advised to avoid these medications or use them only if the benefits outweigh the risks.
Doctors may choose to monitor these individuals closely. Signs of pancreatitis include sudden stomach pain, nausea, vomiting, and fever. If any of these symptoms appear, the medicine should be stopped and the person should be checked by a healthcare provider right away.
Diabetic Retinopathy
Diabetic retinopathy is an eye disease caused by long-term high blood sugar. It affects the blood vessels in the retina and can lead to vision loss if not treated.
Some studies, especially those involving semaglutide, have shown that people with existing diabetic retinopathy may have a higher risk of worsening eye problems when using GLP-1 receptor agonists. This may happen because of how quickly blood sugar levels drop when starting these drugs. Rapid changes in blood sugar can stress already damaged blood vessels in the eye.
For people with moderate to severe retinopathy, eye exams should be done before starting treatment and during follow-up visits. Blood sugar levels may need to be lowered more slowly to avoid making eye problems worse.
Kidney Problems (Renal Impairment)
Kidneys help remove waste from the body and keep fluids in balance. When kidney function is reduced, the body has a harder time processing and removing drugs.
GLP-1 receptor agonists are not directly harmful to the kidneys, but the side effects of these drugs—especially nausea, vomiting, and diarrhea—can cause dehydration. Dehydration can make kidney problems worse, and in rare cases, may lead to acute kidney injury.
People with chronic kidney disease (CKD) should be watched closely when using GLP-1 agonists. This includes checking kidney function through lab tests, staying hydrated, and avoiding other medicines that can damage the kidneys.
Different GLP-1 drugs may be safer at different levels of kidney function. For example, liraglutide and dulaglutide can be used in moderate kidney disease, but exenatide should not be used in severe kidney problems or those on dialysis.
Gallbladder Disease
The gallbladder stores bile, a substance that helps digest fat. GLP-1 receptor agonists may increase the risk of gallstones or inflammation of the gallbladder (cholecystitis). This may be due to the slowing down of digestion caused by these medications.
People who have had gallbladder disease before should talk with their doctor before starting treatment. Signs of gallbladder problems include right upper belly pain, nausea, and yellowing of the skin or eyes. If any of these happen, medical care is needed right away.
The risk of gallbladder disease may be higher in people who lose weight quickly, which often happens with GLP-1 drugs. Regular check-ups and attention to symptoms can help catch problems early.
Heart Conditions
Some GLP-1 receptor agonists have shown benefits for heart health, such as lowering the risk of stroke or heart attack. However, for people with certain heart conditions, these medications may still require caution.
For example, people with fast heart rhythms (tachycardia) or heart failure may need monitoring, especially since some GLP-1 agonists can cause a small increase in heart rate. While this effect is usually mild, it may matter in people with serious heart problems.
Doctors will look at the type of heart condition, other medications being used, and overall heart health before deciding if GLP-1 therapy is a good fit.
People with pancreatitis, diabetic retinopathy, kidney problems, gallbladder disease, or heart issues should use GLP-1 receptor agonists carefully. These medications can offer many benefits, but they also carry risks in certain medical situations. With the right monitoring and medical guidance, many people can use them safely, even with complex health conditions.
Can GLP-1 Agonists Cause Pancreatitis or Pancreatic Cancer?
GLP-1 receptor agonists, such as semaglutide, liraglutide, exenatide, and dulaglutide, are widely used to help manage blood sugar in type 2 diabetes and support weight loss in people with obesity. These medications work by copying the action of a hormone in the gut called GLP-1 (glucagon-like peptide-1). This hormone helps the body release insulin, reduce appetite, and slow down how fast the stomach empties.
As more people begin taking these medications, questions have been raised about their safety, especially regarding the pancreas. The two main concerns are pancreatitis (inflammation of the pancreas) and pancreatic cancer. These concerns are important because the pancreas plays a key role in digestion and blood sugar control.
Understanding Pancreatitis and the Pancreas
Pancreatitis happens when the pancreas becomes inflamed. This can cause sudden and severe belly pain, nausea, vomiting, and fever. In some cases, it can become life-threatening. There are two types of pancreatitis: acute (sudden and short-term) and chronic (long-lasting and ongoing).
Some people with type 2 diabetes already have a higher risk of pancreatitis, even without taking GLP-1 medications. This may be due to high blood sugar levels, high triglycerides, gallstones, or alcohol use. Because of this, it has been hard to know whether GLP-1 agonists raise the risk or if the risk is linked to other conditions common in people with diabetes.
What the Research Says About Pancreatitis
Early reports from patients and doctors suggested a possible link between GLP-1 agonists and pancreatitis. These reports came from post-marketing safety data, meaning they were collected after the drug was approved and used by the public.
Because of those reports, researchers began to study the link more closely. Some small studies and case reports suggested a connection, but larger clinical trials have not shown a clear or strong link.
For example, in large studies like the LEADER trial (which looked at liraglutide) and the SUSTAIN-6 trial (which looked at semaglutide), the number of pancreatitis cases was low and similar between people who took GLP-1 agonists and those who did not. These studies included thousands of patients over several years.
Other studies using health insurance databases have shown mixed results. Some showed a small increase in pancreatitis risk, while others did not. Overall, the current medical understanding is that there may be a small risk of pancreatitis, but it is not clearly proven.
Because pancreatitis can be serious, doctors usually avoid prescribing GLP-1 agonists to anyone who has had it before. The drug labels also warn about this risk and recommend stopping the medicine if symptoms of pancreatitis appear.
What About Pancreatic Cancer?
Pancreatic cancer is rare but very serious. Like pancreatitis, early warning signs are not always clear. Concerns about GLP-1 agonists and pancreatic cancer began around the same time as concerns about pancreatitis. Some believed that repeated or chronic inflammation of the pancreas might lead to cancer over time.
Again, studies have not clearly proven that GLP-1 receptor agonists cause pancreatic cancer. Most large trials have not shown an increase in cancer cases among people taking these medications. However, because pancreatic cancer takes years to develop and is rare, long-term data are still being collected.
A few observational studies have reported a slight increase in cases of pancreatic cancer among people using GLP-1 medications, but these studies cannot prove cause and effect. Many factors, such as age, smoking, obesity, and diabetes itself, can raise the risk of cancer.
Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have reviewed the data. They have not found enough evidence to say that GLP-1 agonists cause pancreatic cancer. However, they continue to monitor new reports and ongoing studies.
How to Stay Safe
Doctors are advised to be cautious when prescribing GLP-1 agonists to people with a history of pancreatitis. Patients who experience severe stomach pain, especially pain that does not go away or spreads to the back, should contact their healthcare provider right away. Nausea and vomiting may also be warning signs. If pancreatitis is suspected, the medication should be stopped immediately.
Blood tests to check the pancreas, such as lipase and amylase, can help diagnose pancreatitis. These tests are sometimes done before starting the medication, especially if the patient has risk factors.
There is no current need to screen for pancreatic cancer in people taking GLP-1 agonists unless they have symptoms or other risk factors. However, it is important for doctors to stay up to date on new research as more long-term safety data become available.
There may be a small risk of pancreatitis with GLP-1 receptor agonists, but the risk of pancreatic cancer remains uncertain. Most large studies have not shown a strong link to either condition. Still, healthcare providers should use these medications carefully in people who have a history of pancreatic problems. Early recognition of symptoms and proper monitoring can help avoid serious harm.
How Do GLP-1 Agonists Affect Kidney Function?
GLP-1 receptor agonists are medicines often used to manage type 2 diabetes and, more recently, to help with weight loss. These medications include drugs such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). They work by helping the body make more insulin, reducing blood sugar levels, slowing stomach emptying, and lowering appetite.
Although GLP-1 agonists are helpful for many people, they can affect the kidneys. Some people who take these medicines have experienced kidney problems, including worsening of kidney function or, in rare cases, acute kidney injury (AKI). Understanding how these drugs may impact the kidneys can help prevent serious harm, especially in people who already have kidney disease.
Dehydration and Kidney Risk
One of the main ways GLP-1 receptor agonists can affect the kidneys is through dehydration. These medications often cause gastrointestinal side effects, especially when treatment is first started or when the dose is increased. Nausea, vomiting, and diarrhea are common. These symptoms can lead to a loss of fluids and salts from the body, which in turn can cause dehydration.
When the body is dehydrated, the kidneys receive less blood flow. This can make the kidneys work harder and may cause injury. In some cases, it can lead to acute kidney injury, which is a sudden loss of kidney function. This condition can be serious and may require medical treatment, including intravenous fluids or even dialysis in extreme cases.
People who are older, have low blood pressure, or are already taking medicines that affect kidney function (such as diuretics or NSAIDs) may be at a higher risk of dehydration and kidney problems while using GLP-1 agonists.
Chronic Kidney Disease and GLP-1 Use
Many people with type 2 diabetes also have chronic kidney disease (CKD). This condition means the kidneys do not filter waste from the blood as well as they should. Using GLP-1 receptor agonists in patients with CKD requires careful monitoring. While some GLP-1 drugs are safe to use in mild or moderate kidney disease, others may not be recommended in more severe cases.
For example:
- Exenatide should not be used in people with severe kidney disease (eGFR below 30 mL/min/1.73 m²) or in those receiving dialysis. It is cleared by the kidneys, and poor kidney function can increase the risk of drug buildup and side effects.
- Liraglutide, semaglutide, and dulaglutide are safer options in people with moderate kidney disease, but healthcare providers usually monitor kidney function regularly during treatment.
- Semaglutide, both the injectable and oral forms, can be used in people with mild to moderate kidney disease. However, oral semaglutide should be used carefully because it may not be absorbed well in patients with severe kidney problems.
Kidney Protection: What the Research Says
Some studies suggest that GLP-1 receptor agonists may actually help protect the kidneys over time. In clinical trials, patients using these drugs showed slower progression of kidney disease compared to those on other treatments. These benefits are believed to be due to improved blood sugar control, reduced blood pressure, weight loss, and less inflammation.
However, the kidney-protective effects are long-term and do not remove the risk of acute kidney injury, especially during times of illness, dehydration, or use of other medications that strain the kidneys.
Monitoring and Safety Tips
To reduce the risk of kidney problems, it is important for people using GLP-1 receptor agonists to stay well-hydrated, especially during the first few weeks of treatment or when increasing the dose. If vomiting, diarrhea, or poor appetite occurs for more than one or two days, medical advice should be sought. These symptoms could lead to dehydration, which may harm the kidneys.
Regular kidney function tests are also important. These tests include measurements of creatinine and estimated glomerular filtration rate (eGFR). They help healthcare providers track how well the kidneys are working and decide whether treatment should be adjusted.
Certain medicines can also increase the risk of kidney problems when taken along with GLP-1 receptor agonists. These include:
- Diuretics (water pills)
- Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen
- ACE inhibitors and ARBs (often used to treat high blood pressure or kidney disease)
Combining these drugs with GLP-1 agonists may raise the chance of dehydration or kidney strain, so extra care is needed.
GLP-1 receptor agonists are effective for managing diabetes and weight, but they can affect kidney health in some people. The main concern is dehydration from nausea, vomiting, or diarrhea, which may lead to acute kidney injury. People with chronic kidney disease or those taking certain medications need regular monitoring and proper hydration to reduce the risk of harm. With careful use and medical supervision, GLP-1 drugs can often be used safely in people with kidney concerns.
Can GLP-1 Agonists Affect the Gallbladder or Cause Gallstones?
GLP-1 receptor agonists are a group of medications that help people with type 2 diabetes or obesity control their blood sugar and manage weight. These drugs work by copying the effects of a natural hormone in the body called glucagon-like peptide-1. They help slow down digestion, reduce hunger, and increase insulin release. While these effects can be helpful, slowing down digestion can also affect the gallbladder and may increase the chance of developing gallbladder problems.
The Role of the Gallbladder
The gallbladder is a small organ under the liver that stores bile. Bile is a liquid made by the liver that helps the body digest fat. When food enters the small intestine, the gallbladder squeezes and releases bile to help break down fat. If the gallbladder does not empty properly or if bile stays in the gallbladder too long, small stones made of cholesterol or bile salts—called gallstones—can form.
Gallstones may stay silent and cause no symptoms, or they can lead to pain, infection, or inflammation. In serious cases, gallstones can block the flow of bile, which can lead to gallbladder infections or require surgery to remove the gallbladder.
How GLP-1 Agonists Affect the Gallbladder
Several studies have shown that GLP-1 receptor agonists can slow down the movement of the digestive system, including the gallbladder. This slower movement means the gallbladder does not empty as often or as fully as it should. When bile sits too long in the gallbladder, it becomes thicker and more likely to form stones. This can increase the risk of gallbladder disease, including cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder).
The risk appears to be higher in people who lose weight quickly. Rapid weight loss is common with GLP-1 medications, especially in people who use them for weight management. Rapid weight loss changes the balance of cholesterol in bile, which can also cause gallstones to form more easily.
Risk Factors for Gallbladder Problems With GLP-1 Use
Not everyone who takes a GLP-1 agonist will develop gallbladder problems. However, certain factors may raise the risk:
- Rapid weight loss: Losing more than 1.5 kg (about 3 pounds) per week increases the risk.
- History of gallstones: People who have had gallstones before are more likely to get them again.
- Obesity: Being overweight raises the risk of gallbladder disease, even before starting a GLP-1 medication.
- Female sex: Women are more likely than men to develop gallstones.
- Age: Gallbladder disease becomes more common with age.
- High cholesterol levels: This can lead to cholesterol-rich bile that forms stones.
- Long-term use: Using a GLP-1 medication for many months or years may increase the risk over time.
Monitoring and Prevention
Health care providers often check for signs of gallbladder issues in people taking GLP-1 agonists. Common signs include pain in the upper right side of the abdomen, nausea, vomiting, and fever. This pain may happen after eating a fatty meal. If a person experiences these symptoms, they should be evaluated for gallstones or other gallbladder problems.
Some steps can help reduce the risk of gallbladder disease while on GLP-1 therapy:
- Gradual weight loss: Avoid losing weight too quickly by following a safe and steady weight loss plan.
- Stay hydrated: Drinking plenty of water helps keep bile thin and flowing.
- Low-fat diet: Eating fewer high-fat foods may lower the stress on the gallbladder.
- Regular follow-ups: Lab tests and check-ins with a doctor help monitor for early signs of gallbladder problems.
Incidence Based on Studies
The number of people who develop gallbladder issues while taking GLP-1 agonists is still being studied. In clinical trials, gallbladder events were seen more often in people taking GLP-1 medications compared to those taking placebo or other diabetes medicines. For example, one large study found that gallbladder disease occurred in about 1.5% to 2% of people on GLP-1 drugs, compared to less than 1% in the control group.
While the increase in risk is not high for everyone, it is enough to require attention, especially in people with other risk factors. Some GLP-1 drugs may have a higher risk than others, possibly due to how strongly they slow digestion or how much weight loss they cause. However, more research is needed to understand the exact differences between them.
GLP-1 receptor agonists are useful medications for managing blood sugar and body weight, but they can affect the gallbladder. By slowing digestion and increasing the chance of gallstones, these drugs may raise the risk of gallbladder disease, especially in people who lose weight quickly or already have other risk factors. Careful monitoring and healthy lifestyle changes can help lower the chance of complications. Understanding these risks allows safer use of GLP-1 agonists under the guidance of a healthcare provider.
Are GLP-1 Agonists Safe During Pregnancy and Breastfeeding?
GLP-1 receptor agonists are not recommended for use during pregnancy or while breastfeeding. These medications, including drugs like semaglutide, liraglutide, and dulaglutide, have not been studied enough in pregnant or breastfeeding people to know if they are fully safe. Because of the way these drugs work in the body and the lack of strong human data, doctors advise stopping GLP-1 medications before becoming pregnant and avoiding them during breastfeeding.
Why GLP-1 Agonists Are Not Recommended in Pregnancy
GLP-1 agonists have not been tested well in pregnant people through clinical trials. Most of the information available comes from animal studies. In these studies, animals were given GLP-1 drugs during pregnancy. Results showed problems with the development of the fetus, including lower birth weight, delayed growth, and sometimes loss of the pregnancy. These effects were usually linked to the dose of the medication—the higher the dose, the more likely there were problems.
Because of these findings, the U.S. Food and Drug Administration (FDA) has not approved any GLP-1 agonists for use during pregnancy. The label on these medications often says that they should only be used if the benefits clearly outweigh the risks, but this is very rare in practice. The risk to the developing baby is considered too high compared to the possible benefits.
Doctors usually recommend stopping GLP-1 drugs at least 2 months before trying to get pregnant. This is because many of these medications stay in the body for a long time, especially the long-acting types like semaglutide. Waiting at least 8 weeks helps make sure the drug is mostly gone from the bloodstream before pregnancy begins.
If someone becomes pregnant while taking a GLP-1 agonist, they should talk to their healthcare provider right away. The doctor will likely stop the medication and help manage blood sugar levels using other, safer options for pregnancy, like insulin.
Pregnancy and the Need for Blood Sugar Control
During pregnancy, keeping blood sugar levels in a healthy range is very important. Poor blood sugar control can lead to problems like preeclampsia, early birth, large birth weight, or birth defects. People with type 2 diabetes who stop using a GLP-1 agonist need another treatment plan during pregnancy. Insulin is often the best choice because it has been studied for a long time and is considered safe to use in pregnancy.
People using GLP-1 drugs for weight loss, rather than for diabetes, also need a different plan. Weight loss is not advised during pregnancy, so these individuals should stop using the medication and focus on gaining a healthy amount of weight under the guidance of their healthcare provider.
Safety During Breastfeeding
There is even less information about GLP-1 agonists and breastfeeding than there is about pregnancy. No good human studies show whether GLP-1 drugs pass into breast milk. Animal studies suggest that these drugs might be present in milk, but it is not known how much or what effect they might have on the baby.
The main concern is that GLP-1 agonists may affect the baby’s growth or digestion. These drugs slow down stomach emptying and change how the body handles sugar. This could possibly affect a baby’s feeding or weight gain if the drug is passed through breast milk.
Because of these unknowns, GLP-1 medications are not recommended while breastfeeding. Healthcare providers usually suggest waiting until breastfeeding has fully stopped before restarting the medication.
Contraception and Family Planning
People who are sexually active and able to become pregnant should use reliable birth control while taking GLP-1 drugs. Since pregnancy is not a safe time to be on these medications, preventing unplanned pregnancy is important. Birth control pills may be less effective in the first few weeks of using GLP-1 drugs due to nausea, vomiting, or delayed stomach emptying. In such cases, doctors may recommend using a backup method, like condoms, especially during the first month of treatment.
For people planning to get pregnant in the future, it is important to talk to a healthcare provider early. They may help adjust medications and suggest when to stop the GLP-1 drug so the body has time to clear it out safely before conception.
GLP-1 receptor agonists are not considered safe for use during pregnancy or breastfeeding due to a lack of solid human data and concerns seen in animal studies. These drugs may cause harm to a developing baby or possibly affect a breastfeeding infant. Anyone taking GLP-1 medications should speak with their doctor before planning a pregnancy and should avoid these drugs while nursing. Safer treatment options are available for people who need to manage blood sugar levels or weight during this time.
What Drug Interactions Should Be Considered With GLP-1 Agonists?
GLP-1 receptor agonists, like semaglutide, liraglutide, dulaglutide, and exenatide, help lower blood sugar and support weight loss. These medications work by slowing down how quickly food leaves the stomach, boosting insulin release when blood sugar is high, and lowering glucagon levels. While these actions are helpful for diabetes and weight control, they can also affect how other drugs work in the body. It’s important to understand these possible interactions to stay safe and avoid serious problems.
Slowed Stomach Emptying and Its Effect on Oral Medications
One of the main effects of GLP-1 agonists is that they slow down the movement of food from the stomach to the intestines. This is called delayed gastric emptying. It helps people feel full longer and eat less, but it can also delay how fast oral medications are absorbed. Some medicines need to be taken on an empty stomach or absorbed quickly to work correctly.
For example, pain relievers, antibiotics, and some seizure medications may not work as well if they take too long to enter the bloodstream. Slower absorption may mean that the drug takes longer to start working or has a weaker effect. In some cases, this could lead to under-treatment or a delay in relief of symptoms.
Healthcare providers may change the time of day a drug is taken or monitor how well the medicine is working. In some situations, switching to a different form of the drug, such as a liquid or injection, might be necessary.
Risk of Low Blood Sugar When Combined With Certain Diabetes Medications
GLP-1 agonists do not usually cause low blood sugar (hypoglycemia) on their own. However, when used together with insulin or medicines called sulfonylureas (like glipizide or glyburide), the chance of hypoglycemia goes up. This is because those other medicines also lower blood sugar, and the effects can add up.
Signs of low blood sugar include shakiness, dizziness, sweating, hunger, confusion, or even fainting. To lower the risk, the dose of insulin or the sulfonylurea may need to be reduced when starting a GLP-1 agonist. Regular blood sugar checks help detect any problems early.
Interactions With Oral Contraceptives
Women who take birth control pills should know that delayed stomach emptying may affect how the body absorbs oral contraceptives. If the pill is not absorbed properly, it might not work well, raising the chance of pregnancy.
In some cases, it is recommended to use another method of birth control, such as condoms, or to use a non-oral option like a patch or injection. Women should talk with their healthcare provider to decide what is safest.
Antibiotics and Other Time-Sensitive Medications
Some antibiotics must reach a certain level in the blood to be effective. If the absorption is delayed by a GLP-1 agonist, the antibiotic may not work well. This can make it harder to treat infections.
The same is true for other drugs that require fast action, like medications for migraine attacks or fast-acting pain relievers. When these medicines are taken with GLP-1 agonists, they may not work as expected. A healthcare provider might suggest taking the other medicine at a different time or using a different drug.
Thyroid Hormone Replacement (Levothyroxine)
Levothyroxine is a medicine used to treat low thyroid levels. It is often taken first thing in the morning before food. GLP-1 agonists may delay how quickly this medicine is absorbed. This could affect thyroid levels in the body and make the treatment less effective.
To avoid this issue, levothyroxine should be taken at least 30 to 60 minutes before food and several hours apart from the GLP-1 agonist, especially when the GLP-1 drug is taken orally (like oral semaglutide). Blood levels of thyroid hormones may need to be monitored more closely to make sure they stay in the right range.
Other Considerations and Monitoring
Not all medicines interact with GLP-1 agonists, but because of the way these drugs affect the stomach, it’s important to review all medications with a healthcare provider. Vitamins, supplements, and even over-the-counter drugs may also be affected. Keeping a full and updated list of medications helps reduce the chance of problems.
Anyone starting a GLP-1 agonist should be closely watched for signs that other medicines are not working properly. Dose adjustments or timing changes can often solve these problems.
Understanding these drug interactions can help prevent serious side effects and make sure all medicines work as they should. With careful planning and good communication between patients and healthcare providers, GLP-1 agonists can be used safely alongside other medications.
How Should GLP-1 Agonists Be Started and Titrated to Minimize Side Effects?
Starting GLP-1 receptor agonists the right way can help reduce unwanted side effects, especially those that affect the stomach and digestion. These medicines work by slowing down how fast the stomach empties and by affecting hunger signals in the brain. Because of this, many people feel nausea or get full quickly when beginning treatment. Titration, or slowly increasing the dose over time, helps the body adjust to the medication. This process lowers the chance of uncomfortable symptoms and makes the treatment more successful in the long run.
Why Titration Is Important
GLP-1 agonists, such as semaglutide, liraglutide, and dulaglutide, often cause stomach-related side effects. These include nausea, vomiting, bloating, constipation, and diarrhea. These problems usually appear when the medication is started or when the dose is increased. Titration helps by allowing the body to slowly get used to the changes the medicine causes in the gut and brain.
When titration is skipped or rushed, the risk of side effects increases. In some cases, the symptoms become so uncomfortable that people stop taking the medication. Slowing down the dose increases helps prevent this outcome and supports long-term use.
General Titration Schedules by Medication
Each GLP-1 agonist has its own starting dose and schedule for increasing the dose. Here are common guidelines for some widely used medications:
- Semaglutide (Ozempic):
Start at 0.25 mg once weekly for four weeks. Then increase to 0.5 mg once weekly. After four weeks at 0.5 mg, the dose can be increased to 1.0 mg weekly if needed. Some patients may be prescribed up to 2.0 mg for better control, but only if tolerated well. - Liraglutide (Victoza):
Begin at 0.6 mg once daily for at least one week. Then increase to 1.2 mg daily. If more glucose control is needed, the dose can go up to 1.8 mg after another week or more. - Dulaglutide (Trulicity):
Start at 0.75 mg once weekly. The dose may be increased to 1.5 mg after four weeks. For additional benefits, higher doses of 3.0 mg or 4.5 mg are sometimes used, but only when lower doses are well-tolerated.
These schedules are only general examples. Doctors may adjust the plan based on how a person feels, their medical conditions, and their blood sugar levels.
Diet and Eating Habits That Help
What and how a person eats during GLP-1 therapy can also affect how the medicine feels in the body. Small changes in diet and eating habits can reduce side effects and improve comfort.
- Eat smaller meals:
GLP-1 agonists slow stomach emptying, so food stays in the stomach longer. Eating large meals can cause bloating, nausea, or vomiting. Smaller meals are easier to digest and reduce strain on the stomach. - Avoid greasy or fatty foods:
High-fat foods digest slowly and can increase nausea. Choosing low-fat meals and snacks can lessen stomach problems. - Eat slowly and chew food well:
Eating too fast makes it harder for the stomach to manage food, especially when under the effects of GLP-1 drugs. Slower eating helps the brain catch up with the feeling of fullness and reduces the chance of overeating. - Stay hydrated:
Drinking water throughout the day helps prevent constipation, which can happen with GLP-1 therapy. Sipping water between meals is better than drinking large amounts with meals, which may cause fullness or discomfort.
When to Stay at a Lower Dose Longer
Not everyone tolerates dose increases at the same speed. Some people may need to stay at a lower dose for longer than the usual schedule. This approach is helpful if nausea or other stomach issues are strong, or if there are other health concerns.
If side effects do not improve after a few weeks, a doctor may recommend pausing dose increases or even lowering the dose. Staying at a lower level for a longer time is better than stopping the medication completely. In some cases, side effects wear off after several weeks of steady use.
Signs to Watch During Titration
Although side effects are common, some symptoms may signal more serious problems. Severe vomiting, signs of dehydration (like dry mouth or dizziness), or strong belly pain may require medical attention. Keeping a journal of symptoms during the first months of treatment can help the healthcare provider decide whether dose changes are needed.
Starting GLP-1 agonists with the right dose and increasing slowly over time is key to reducing side effects. Following the suggested titration schedule, eating small and low-fat meals, staying hydrated, and listening to the body’s response can make treatment safer and more effective. Patience during the early weeks helps many people adjust to the medicine and stay on track with their treatment goals.
When Should GLP-1 Therapy Be Discontinued?
GLP-1 receptor agonists are helpful medicines for people with type 2 diabetes and obesity. However, there are times when these drugs should be stopped. It is important to know when stopping treatment is the right and safe choice. Certain side effects or health conditions can make continuing GLP-1 therapy dangerous. Knowing the warning signs and when to stop can help avoid serious problems.
Severe Gastrointestinal Symptoms
One of the most common reasons to stop a GLP-1 agonist is severe stomach or bowel side effects. While mild nausea or diarrhea is common, symptoms that do not go away or become worse may be a sign of a serious problem.
Some people develop severe nausea, vomiting, or diarrhea that causes dehydration. This can lead to weakness, dizziness, or low blood pressure. If a person cannot keep fluids down or begins to lose weight too quickly, stopping the drug may be necessary. In some cases, the doctor may try restarting the drug later at a lower dose once the symptoms improve.
Signs of Pancreatitis
Pancreatitis is a rare but serious side effect linked to GLP-1 agonists. Pancreatitis is swelling and inflammation of the pancreas. It can be dangerous if not treated early. People taking a GLP-1 drug should stop treatment right away if they show signs of pancreatitis.
These signs include:
- Sudden and severe pain in the upper stomach
- Pain that may spread to the back
- Nausea or vomiting that won’t go away
- Fever or a fast heart rate
If pancreatitis is suspected, the medicine should be stopped and medical help should be sought immediately. The doctor may check blood tests or order an ultrasound or CT scan. If pancreatitis is confirmed, the GLP-1 agonist should not be restarted.
Allergic Reactions
In rare cases, people may have an allergic reaction to GLP-1 drugs. Symptoms can include:
- Swelling of the face, lips, tongue, or throat
- Trouble breathing or swallowing
- Hives or a rash
These can be signs of a serious allergic reaction called anaphylaxis. If this happens, the medicine must be stopped right away, and emergency medical help should be given. Once a severe allergic reaction occurs, the person should not use that medication again.
Thyroid Concerns
GLP-1 agonists have been linked to thyroid tumors in animal studies. Although this has not been proven in people, caution is still advised. People with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take these drugs.
If a thyroid lump or swelling is found, or if hoarseness or difficulty swallowing occurs, the drug should be stopped while tests are done. An ultrasound or blood test for calcitonin (a thyroid hormone) may be ordered. If a thyroid tumor is found, the GLP-1 medicine should be discontinued.
Kidney Problems
Severe vomiting or diarrhea caused by GLP-1 drugs can lead to dehydration. Dehydration can reduce blood flow to the kidneys and cause acute kidney injury. People with existing kidney disease are more at risk.
Signs of kidney problems include:
- Swelling in the legs or ankles
- Less urine than usual
- Tiredness or confusion
- Shortness of breath
If these symptoms develop, the doctor may stop the drug and test kidney function. In most cases, kidney problems get better after stopping the medicine and giving fluids.
Vision Changes or Diabetic Retinopathy
Some people using GLP-1 agonists may notice changes in vision. There have been reports of worsening diabetic eye disease (diabetic retinopathy), especially when blood sugar improves quickly.
Signs may include:
- Blurry vision
- Seeing floaters or dark spots
- Sudden vision loss
If this happens, the medicine may be paused, and an eye specialist should be consulted. For people with a history of severe eye disease, close monitoring is important.
Monitoring and Medical Guidance
It is very important to have regular check-ups while taking a GLP-1 agonist. Lab tests and physical exams can help find problems early. Doctors may check:
- Blood sugar and A1c
- Kidney function (creatinine and eGFR)
- Signs of pancreatitis or thyroid problems
- Body weight and hydration status
If side effects appear or lab tests show problems, the doctor may lower the dose, change the drug, or stop it completely.
Stopping the Medicine
Most GLP-1 drugs can be stopped without tapering. They do not cause withdrawal symptoms. However, blood sugar may rise after stopping, and weight may increase again. A plan should be made with a healthcare provider for how to manage diabetes or weight after stopping the drug.
Some people may be switched to a different type of medicine, depending on their needs and risks. If the reason for stopping the drug was mild, such as nausea, it may be restarted later at a lower dose. If a serious side effect occurred, restarting is not safe.
Stopping a GLP-1 agonist may be needed for serious stomach symptoms, signs of pancreatitis, allergic reactions, kidney or thyroid issues, or vision changes. Regular check-ups can catch these problems early. Knowing the signs and acting quickly helps prevent harm and protects health. Always follow medical advice when deciding to stop or restart treatment.
Conclusion
GLP-1 receptor agonists have become an important treatment option for people with type 2 diabetes and for those who are managing obesity. These medications work by mimicking a natural hormone in the body that helps control blood sugar levels, slow digestion, and reduce appetite. They can help improve blood sugar and support weight loss. However, like any medication, GLP-1 agonists can have side effects and may not be safe for everyone. Understanding when they should not be used and what side effects may happen is important to avoid harm and protect patient health.
Certain people should not take GLP-1 receptor agonists. These are called contraindications. For example, anyone with a personal or family history of medullary thyroid cancer should not use these medicines. The same is true for people with multiple endocrine neoplasia syndrome type 2 (MEN 2). These conditions are rare, but they are serious, and studies in animals have raised concerns about thyroid tumors with GLP-1 drugs. These medicines should also be avoided by anyone who has had a serious allergic reaction to the drug or one of its ingredients. People with a condition that slows the emptying of the stomach, like gastroparesis, should also avoid GLP-1 agonists because the medication can make the condition worse.
There are also some conditions where doctors must use caution. For example, anyone with a history of pancreatitis may face a higher risk of getting pancreatitis again when using GLP-1 agonists. Although studies are still being done, it is best to be careful and watch for warning signs. People with diabetic eye disease, especially those with diabetic retinopathy, may have a higher risk of worsening symptoms when starting GLP-1 treatment. Kidney problems are another concern. GLP-1 drugs can lead to dehydration due to nausea, vomiting, or diarrhea. This can harm the kidneys, especially in people who already have kidney disease. Gallbladder problems, including gallstones and inflammation, have also been reported. Patients who are overweight or losing weight quickly may be at higher risk. These conditions do not always mean the medicine cannot be used, but they do require extra attention and regular follow-up.
Many common side effects of GLP-1 receptor agonists are related to the digestive system. These include nausea, vomiting, constipation, and diarrhea. Most of these symptoms are mild and tend to go away after a few weeks. But for some people, the symptoms are strong enough to stop treatment. Starting with a low dose and slowly increasing the amount over time can help reduce these problems. Eating small, low-fat meals may also help ease symptoms. Other common effects include headaches, tiredness, and reactions at the injection site. Serious side effects are less common but include pancreatitis, kidney injury, gallbladder disease, and possible thyroid tumors.
People who are pregnant or planning to become pregnant should not use GLP-1 receptor agonists. Animal studies have shown possible harm to the baby, and there are not enough studies in humans. Most doctors recommend stopping the medicine at least two months before trying to get pregnant. Breastfeeding is also not advised while taking this medicine, because it is not known if the drug passes into breast milk or if it could affect the baby.
GLP-1 drugs can also affect how the body absorbs other medicines. Since they slow the emptying of the stomach, pills taken by mouth may be absorbed more slowly. This can be important for drugs like birth control pills, thyroid medicine, and certain antibiotics. GLP-1 agonists also increase the risk of low blood sugar when taken with insulin or sulfonylureas, so doses of those drugs may need to be adjusted.
To reduce the chance of side effects, doctors usually start with a low dose and increase it slowly. This helps the body get used to the medicine. Patients should be told how to recognize warning signs, such as strong stomach pain, vision changes, or swelling in the neck. These symptoms may mean a serious side effect and should be checked right away. If a person needs to stop the medication, this can usually be done without tapering. But any decision to stop should be based on symptoms, lab tests, and the person’s overall health.
GLP-1 receptor agonists can be very helpful medications, but they are not right for everyone. Knowing who should not take these drugs and what side effects to look out for helps keep people safe. Doctors and patients must work together to weigh the benefits and risks. Regular check-ups, lab tests, and good communication are key. With careful use, these medicines can support better blood sugar control and weight management while avoiding serious harm.
Research Citations
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., et al. (2010). Glucagon‑like peptide‑1 receptor agonists activate rodent thyroid C‑cells causing calcitonin release and C‑cell proliferation. Endocrinology, 151(4), 1473–1486.
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN‑6). New England Journal of Medicine, 375(19), 1834–1844.
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6). New England Journal of Medicine, 381(9), 841–851.
Faillie, J.-L., Yu, O. H. Y., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L. (2014). Glucagon‑like peptide‑1 receptor agonists and pancreatitis: A meta‑analysis. Digestive and Liver Disease, 46(3), 199–204.
Monami, M., Dicembrini, I., & Mannucci, E. (2017). Safety issues with glucagon‑like peptide‑1 receptor agonists: Pancreatitis, pancreatic cancer and cholelithiasis—Data from randomized controlled trials. Diabetes, Obesity and Metabolism, 19(9), 1233–1241.
[Author group]. (2022). Association of GLP‑1 receptor agonist use with gastrointestinal adverse events (gallbladder disease, pancreatitis, bowel obstruction, gastroparesis). JAMA.
Shen, W., Wang, B., Wang, Y., & Wang, C. (2023). GLP‑1 receptor agonists and delayed gastric emptying/gastroparesis: Implications for peri‑anesthesia risk. Journal of Clinical Medicine, 12, [Article number].
Nakatani, Y., Kawakami, A., et al. (2022). Glucagon‑like peptide‑1 receptor agonists and biliary disease: A systematic review and meta‑analysis. JAMA Internal Medicine, 182(5), 513–[pages].
Filippatos, T. D., et al. (2024). Pancreatitis risk associated with GLP‑1 receptor agonists in a comorbidity‑free type 2 diabetes population. Journal of Clinical Endocrinology & Metabolism, 109([issue]), [pages].
Rosol, T. J. (2013). On‑target effects of GLP‑1 receptor agonists on thyroid C‑cells in rats and mice. Toxicologic Pathology, 41(2), 303–309.
Questions and Answers: GLP-1 Contraindications
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
They are not absolutely contraindicated, but caution is advised in patients with a history of pancreatitis.
No, they are generally contraindicated in patients with severe gastrointestinal disorders such as gastroparesis.
No, they are not indicated and generally not recommended in patients with type 1 diabetes.
No, GLP-1 receptor agonists are contraindicated or not recommended during pregnancy due to lack of safety data.
Severe renal impairment may be a contraindication depending on the specific agent; caution or dose adjustment may be required.
No, GLP-1 RAs are contraindicated in patients with diabetic ketoacidosis.
Yes, known hypersensitivity to the drug or its components is a contraindication.
Most GLP-1 RAs are not approved for use in pediatric populations; age-specific contraindications apply.
Not strictly contraindicated, but caution is advised as GLP-1 RAs may increase the risk of gallbladder-related events.
Dr. Jay Flottman
Dr. Jay Flottmann is a physician in Panama City, FL. He received his medical degree from University of Texas Medical Branch and has been in practice 21 years. He is experienced in military medicine, an FAA medical examiner, human performance expert, and fighter pilot.
Professionally, I am a medical doctor (M.D. from the University of Texas Medical Branch at Galveston), a fighter pilot (United States Air Force trained – F-15C/F-22/AT-38C), and entrepreneur.